Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
William P. QuinnPresident, CEO and CFO | Bolt BiotherapeuticsBOLT | Open-market buy | 25/12/05 | 02/04 | 125 sh | $4.61 | $576.25 | +5.7% |
Sarah NemecSenior VP, Finance and PAO | Bolt BiotherapeuticsBOLT | Open-market buy | 25/12/05 | 02/04 | 125 sh | $4.61 | $576.25 | +9.7% |
William P. QuinnPresident, CEO and CFO | Bolt BiotherapeuticsBOLT | Open-market buy | 25/06/06 | 25/10/24 | 125 sh | $5.49 | $686.25 | +6.1% |
Sarah NemecSenior VP, Finance and PAO | Bolt BiotherapeuticsBOLT | Open-market buy | 25/06/06 | 25/10/24 | 125 sh | $5.49 | $686.25 | +15.3% |
Bolt BiotherapeuticsBOLT | Open-market buy | 24/06/06–24/12/16 | 25/05/05 | 5,000 sh2 trades | $0.57avg. | $2,850 | +13.8% | |
Bolt BiotherapeuticsBOLT | Open-market buy | 24/06/06–24/12/16 | 25/05/05 | 5,000 sh2 trades | $0.57avg. | $2,850 | +43.0% | |
Bolt BiotherapeuticsBOLT | Open-market buy | 23/06/06–23/12/12 | 23/12/13 | 11,829 sh3 trades | $0.95avg. | $11,233.22 | +48.4% | |
Bolt BiotherapeuticsBOLT | Open-market sale | 23/11/29–23/11/30 | 23/12/01 | 148,884 sh4 trades | $0.87avg. | $129,330.49 | −37.2% | |
Bolt BiotherapeuticsBOLT | Open-market sale | 23/11/21 | 23/11/22 | 1,943 sh2 trades | $0.90avg. | $1,748.7 | −0.7% | |
Bolt BiotherapeuticsBOLT | Open-market sale | 23/11/21 | 23/11/22 | 3,400 sh3 trades | $0.90avg. | $3,060 | −3.0% | |
Bolt BiotherapeuticsBOLT | Open-market sale | 23/11/16–23/11/20 | 23/11/20 | 49,173 sh6 trades | $0.93avg. | $45,675.45 | −15.4% | |
Bolt BiotherapeuticsBOLT | Open-market sale | 23/11/16–23/11/20 | 23/11/20 | 86,054 sh9 trades | $0.93avg. | $79,933.22 | −43.2% |